2021 Revenues ($USD) : $9,913,000,000
2021 R&D spend : $1,143,000,000
2021 Number of Employees : 38,000
Fiscal Year End : 12/31/2020
Key People : Michael Mahoney, chairperson and CEO; Daniel Brennan, EVP and CFO; Vance Brown, SVP, general counsel and corporate secretary; Art Butcher, EVP and president, Asia Pacific; Wendy Carruthers, SVP, human resources; Jodi Eddy, SVP and chief information and digital officer; Joseph Fitzgerald, EVP and president, interventional cardiology; Edward Mackey, EVP, global operations; Ian Meredith, EVP and global chief medical officer; Jeff Mirviss, EVP and president, peripheral interventions; Maulik Nanavaty, SVP and president, neuromodulation; Scott Olson, SVP and president, rhythm management; David Pierce, EVP and president, MedSurg and president, endoscopy; Meghan Scanlon, SVP and president, urology and pelvic health; Brad Sorenson, SVP, manufacturing and supply chain; Eric Thépaut, EVP and president, EMEA.

About the company: Marlborough, Massachusetts–based Boston Scientific is developing numerous devices across its six businesses: endoscopy, interventional cardiology, neuromodulation, peripheral interventions, rhythm management and urology and pelvic health. The company was the first to receive FDA clearance for a single-use duodenoscope, securing a 510(k) for the Exalt Model D in 2019. It was designed for endoscopic retrograde cholangiopancreatography procedures as an alternative to reusable duodenoscopes to eliminate the use of reprocessing and repairs. Boston Scientific has since received FDA clearance for its Exalt Model B single-use bronchoscope. The company also makes well-known devices for structural heart and coronary therapies, such as the Watchman for left atrial appendage closure. It makes drug-eluting stents, catheters, balloons, guidewires, TAVR devices and specializes in cerebral embolic protection. Deep brain stimulation for chronic pain treatment and other minimally invasive therapies for arterial disease, venous disease and cancer are also in its product portfolio. Boston Scientific's Emblem MRI S-ICD system is one of the industry's first MR-conditional subcutaneous implantable defibrillators (S-ICD) to provide protection for patients at risk for sudden cardiac death. Throughout 2021, the company has continued on an acquisition spree. Early in the year, Boston Scientific acquired Preventice Solutions and its remote patient monitoring technology for up to $1.2 billion. Lumenis and its surgical portfolio of laser systems, fibers and urology and otolaryngology procedures was acquired by the company for $1.1 billion earlier this year as well. It also purchased Farapulse for $450 million and Baylis Medical for $1.75 billion this year. –DK